RECRUITING

Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

It is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. Researchers will test the effects of inflammation and lipolysis regulation in people before and after bariatric surgery (sleeve gastrectomy) to answer these questions.

Official Title

Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis

Quick Facts

Study Start:2019-08-01

Study Completion:2025-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03868592

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* BMI 40 - 50 kg/m2. * Mo active physical illness that would interfere with mobility or weight loss after bariatric surgery	* Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose ≥126 mg/dL * Active coronary artery disease * Participation in structured exercise (\>2 times per week for 30 minutes or longer) * Smoking * Medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids) * Renal insufficiency (serum creatinine \> 1.5mg/dl) * Chronic active liver disease (Bilirubin \> 17mmol/L, AST \> 144 IU/L, or ALT\>165IU/L) * Pregnancy or breastfeeding.

Inclusion Criteria

Exclusion Criteria

* BMI 40 - 50 kg/m2.
* Mo active physical illness that would interfere with mobility or weight loss after bariatric surgery

* Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose ≥126 mg/dL
* Active coronary artery disease
* Participation in structured exercise (\>2 times per week for 30 minutes or longer)
* Smoking
* Medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids)
* Renal insufficiency (serum creatinine \> 1.5mg/dl)
* Chronic active liver disease (Bilirubin \> 17mmol/L, AST \> 144 IU/L, or ALT\>165IU/L)
* Pregnancy or breastfeeding.

Contacts and Locations

Principal Investigator

Michael D Jensen, MD

PRINCIPAL_INVESTIGATOR

Mayo Clinic

Study Locations (Sites)

Mayo Clinic

Rochester, Minnesota, 559055

United States

Collaborators and Investigators

Sponsor: Mayo Clinic

Michael D Jensen, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-08-01

Study Completion Date2025-05

Study Record Updates

Study Start Date2019-08-01

Study Completion Date2025-05

Terms related to this study

Additional Relevant MeSH Terms

Obesity, Morbid